Licensed indications for Taxotere extended

The licensed indications for the antineoplastic agent Taxotere (docetaxel) have been extended allowing the product to be used in combination with cisplatin and 5-fluorouracil in metastatic gastric adenocarcinoma, including adenocarcinoma of the gastro-oesophageal junction, in patients who have not received prior chemotherapy for metastatic disease.

The extension to the licence follows the results of a multi-centre clinical trial in which it was shown that docetaxel in combination with cisplatin and 5-FU produced a significantly longer time to progression of the disease and a significant reduction in mortality compared to cisplatin and 5-FU alone.

Patients must be adequately hydrated, be premedicated with antiemetics and receive prophylactic G-CSF to mitigate the risk of haematological toxicities.

Further information: Sanofi Aventis, 1 Onslow Street, Guildford, Surrey GU1 4YS. Tel: (01483) 505515.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more